How to buy BioNTech (BNTX) shares in the UK

Learn how to easily invest in BioNTech shares.

Latest updates

Our experts keep on top of the markets to bring you the latest on what's shaking up stock prices.

10 August 2022: BioNTech has released its second quarterly earnings report for the year with results lower than analysts expected. It reported revenues of €3.2 billion (£2.71 billion), 22% lower than was predicted. Its earnings per share (EPS) was reported to be €6.45 (£5.46), nearly 9% below predictions. BioNTech and Pfizer have announced that they are beginning a clinical trial for a vaccine against new COVID-19 variants.

29 July 2022: We're expecting BioNTech to release an earnings report on August 08, 2022. Analyst predictions suggest that it will have an earnings per share (EPS) of $6.54 (£5.48).

BioNTech is a German biotechnology company founded in 2008. BioNTech's COVID-19 vaccine (co-developed with Pfizer) propelled the company into the spotlight in 2020 with the announcement of its 90% efficacy rate. Over the last 12 months, BioNTech's share price has risen by a staggering 243.58% from $104.96.

BioNTech SE (BNTX) is a publicly traded biotechnology business based in Germany. In the week up to 3 August BioNTech shares surged 14.34% to a closing position of $178.23. However, over the last 12 months, BioNTech's share price has fallen by an alarming 57.13% from $374.02. BioNTech is listed on the NASDAQ and employs 3,082 staff. All prices are listed in US Dollars.

How to buy shares in BioNTech

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: BNTX in this case.
  5. Research BioNTech shares. The platform should provide the latest information available.
  6. Buy your BioNTech shares. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Fees for buying 5x BioNTech shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $10 £3.30
£663.78 total
Capital at risk
IG Share Dealing logo £0 £250 £11.58
£672.06 total
Capital at risk
Freetrade logo £0 £1 £2.97
£663.45 total
Capital at risk
Fineco logo £0 No minimum £6.60
£667.09 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £18.55
£679.04 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £0.66
£661.14 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £17.90
£678.38 total
Capital at risk
Stake logo £0 £50 £3.30
£663.78 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £17.76
£678.24 total
Capital at risk

Full comparison of share dealing platforms

BioNTech share price (NASDAQ:BNTX)

Use our graph to track the performance of BNTX stocks over time.

BioNTech price performance over time

Historical closes compared with the last close of $160.35

1 week (2022-08-05) -12.43%
1 month (2022-07-13) -3.76%
6 months (2022-02-10) -4.29%
1 year (2021-08-13) -57.50%
2 years (2020-08-13) 125.85%

Is it a good time to buy BioNTech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Promoted
eToro Free Stocks

Invest in BioNTech shares with 0% commission

  • Start investing from as little as $10
  • Pay no stamp duty on UK shares
  • Join 25 million users who trust their investments with eToro
Other fees apply. Capital at risk

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is BioNTech under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

BioNTech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, BioNTech shares trade at around 3x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, BioNTech's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

PEG ratio

BioNTech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.0449. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioNTech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider BioNTech's PEG ratio in relation to those of similar companies.

EBITDA

BioNTech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $17.8 billion (£14.6 billion).

The EBITDA is a measure of a BioNTech's overall financial performance and is widely used to measure a its profitability.

To put that into context you can compare it against similar companies.

BioNTech shares at a glance

Information last updated 2022-08-12.
Open$160.5
High$161.6
Low$158.6
Close$160.35
Previous close$158.59
Change$1.76
Change %1.1098%
Volume480,674
Information last updated 2022-08-08.
52-week range$117.08 - $412.5359
50-day moving average$155.3144
200-day moving average$191.5039
Wall St. target price$243.86
PE ratio3.2575
Dividend yield$0 (1.33%)
Earnings per share (TTM)$50.99

BioNTech share dividends

1.3%

Dividend yield: 1.33% of stock value

1.3%

Forward annual dividend yield: 1.33% of stock value

5.4%

Dividend payout ratio: 5.44% of net profits

BioNTech has recently paid out dividends equivalent to 1.33% of its share value annually.

BioNTech has paid out, on average, around 5.44% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.33% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 1.33% return on their shares, in the form of dividend payments. In BioNTech's case, that would currently equate to about $0 per share.

While BioNTech's payout ratio might seem low, this can signify that the company is investing more in its future growth.

BioNTech's most recent dividend payout was on 17 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 2 June 2022 (the "ex-dividend date").

BioNTech's dividend yield is perhaps best considered in relation to those of similar companies.

Share price volatility

Over the last 12 months, BioNTech's shares have ranged in value from as little as $117.08 up to $412.5359. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioNTech's is -0.0761. This would suggest that BioNTech's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, BioNTech has bucked the trend.

To put BioNTech's beta into context you can compare it against those of similar companies.

Frequently asked questions

More guides on Finder

  • How to buy Honda (HNDAF) shares in the UK

    Ever wondered how to buy shares in Honda? We explain how and compare a range of providers that can give you access to many brands, including Honda.

  • How to buy Duolingo (DUOL) shares in the UK

    You can own Duolingo shares in just a few minutes by using an online share dealing platform. Our table lets you compare the UK’s leading share dealing accounts to find the right one for you.

  • Earnings calendar

    “Earnings season” is the unofficial term for the period in which companies report their earnings for the latest quarter. Here’s what we’re expecting to see.

  • Top 10 stock market myths

    Find out the top 10 most popular stock market myths and whether or not there’s any truth to them.

  • How to sell shares

    Find out how you can sell your shares in the UK.

  • How to buy Panasonic (0QYR) shares

    Ever wondered how to buy shares in Panasonic? We explain how and compare a range of providers that can give you access to many brands, including Panasonic.

  • What to do if the stock market crashes

    Find out what to do if the stock market crashes, the risks involved, plus a range of different strategies to consider when investing.

  • Freetrade vs interactive investor

    Both Freetrade and interactive investor offer the chance to trade on the go with their mobile apps. Find out how they compare on features.

  • Freetrade vs eToro

    Both Freetrade and eToro offer the chance to trade without paying any commission. Find out how they compare on features.

  • iWeb review

    We took a look at iWeb to find out about its products, features, fees and financial services. Read our guide to learn more about this platform.

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site